Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis
- PMID: 16267000
- DOI: 10.1158/0008-5472.CAN-05-0901
Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis
Abstract
Dissemination to draining lymph nodes is a frequent first step in prostate cancer metastasis. Although tumors metastasize to lymph nodes via the lymphatics, the importance of lymphangiogenesis in mediating the process remains controversial. Here, we inhibit intratumoral lymphangiogenesis in s.c. and surgical orthotopic implantation mouse models of human prostate cancer using several strategies. Stable expression of small interfering RNAs (siRNA) targeted against human vascular endothelial growth factor-C (VEGF-C) in PC-3 cells reduced intratumoral lymphatics by 99% in s.c. tumors, indicating that tumor-secreted VEGF-C is necessary for lymphangiogenesis. Expression of siRNAs against human VEGF-A somewhat reduced tumor lymphangiogenesis. Secretion of a soluble VEGF receptor-3/Flt4 fusion protein by PC-3 cells reduced intratumoral lymphatics by 100% in s.c. tumors. Combination of soluble Flt4 and VEGF-C siRNA yielded >92% reduction of intratumoral lymphatics in orthotopic prostate tumors. However, metastasis to lymph nodes was not significantly affected regardless of intratumoral lymphatic vessel density. The abundance of marginal lymphatics at the tumor-stromal interface was unchanged in orthotopic tumors whose intratumoral lymphatics were inhibited, suggesting that these marginal vessels could be sufficient for lymph node metastasis. Hematogenous metastasis (blood tumor burden, lung metastasis) correlated with degree of lymph node invasion. We also analyzed the lymphatics in spontaneous transgenic adenocarcinomas of the mouse prostate which metastasize to lymph nodes. Progression from well-differentiated prostate intraepithelial neoplasia to metastatic, undifferentiated adenocarcinoma was accompanied by loss of lymphatics. These results suggest that tumor-secreted VEGF-C and, to a lesser extent, VEGF-A, are important for inducing prostate cancer intratumoral lymphangiogenesis but are unnecessary for lymph node metastasis.
Similar articles
-
Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.Cancer Res. 2006 Oct 1;66(19):9566-75. doi: 10.1158/0008-5472.CAN-06-1488. Cancer Res. 2006. PMID: 17018613
-
Molecular control of lymphatic metastasis.Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Ann N Y Acad Sci. 2008. PMID: 18519975 Review.
-
Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.Cancer Gene Ther. 2008 Dec;15(12):776-86. doi: 10.1038/cgt.2008.43. Epub 2008 Jul 25. Cancer Gene Ther. 2008. PMID: 18654613
-
Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.Anat Rec (Hoboken). 2010 May;293(5):802-12. doi: 10.1002/ar.21096. Anat Rec (Hoboken). 2010. PMID: 20225197
-
Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.J Leukoc Biol. 2006 Oct;80(4):691-6. doi: 10.1189/jlb.1105653. Epub 2006 Jun 22. J Leukoc Biol. 2006. PMID: 16793912 Review.
Cited by
-
Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis.Cancers (Basel). 2023 Nov 30;15(23):5671. doi: 10.3390/cancers15235671. Cancers (Basel). 2023. PMID: 38067373 Free PMC article.
-
Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges.Cancers (Basel). 2023 May 23;15(11):2885. doi: 10.3390/cancers15112885. Cancers (Basel). 2023. PMID: 37296848 Free PMC article. Review.
-
Lymph nodes: at the intersection of cancer treatment and progression.Trends Cell Biol. 2023 Dec;33(12):1021-1034. doi: 10.1016/j.tcb.2023.04.001. Epub 2023 May 4. Trends Cell Biol. 2023. PMID: 37149414 Review.
-
The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue.Cell Biosci. 2023 Mar 20;13(1):60. doi: 10.1186/s13578-023-01008-4. Cell Biosci. 2023. PMID: 36941697 Free PMC article. Review.
-
The role of tumor neogenesis pipelines in tumor progression and their therapeutic potential.Cancer Med. 2023 Jan;12(2):1558-1571. doi: 10.1002/cam4.4979. Epub 2022 Jul 13. Cancer Med. 2023. PMID: 35832030 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous